Karádi É - Search Results

1

Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters.

Ritter Z, Papp L, Zámbó K, Tóth Z, Dezső D, Veres DS, Máthé D, Budán F, Karádi É, Balikó A, Pajor L, Szomor Á, Schmidt E, Alizadeh H. Ritter Z, et al. Among authors: karadi e. Front Oncol. 2022 Jun 8;12:820136. doi: 10.3389/fonc.2022.820136. eCollection 2022. Front Oncol. 2022. PMID: 35756658 Free PMC article.

2

[Low mean cell hemoglobin is a reliable marker for iron deficiency screening].

Kellner SV, Kellner Á, Haragh A, Dombi P, Karádi É, Rajnics P, Kollár B, Alizadeh H, Ghosh M, Liposits A, Moizs M, Egyed M. Kellner SV, et al. Among authors: karadi e. Orv Hetil. 2016 Jan 3;157(1):35-8. doi: 10.1556/650.2016.30328. Orv Hetil. 2016. PMID: 26708685 Hungarian.

3

A potentially new thromboembolic event scoring system in polycythaemia vera patients: An audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia register.

Karadi E, Dombi P, Korom VG, Kovacs E, Herczeg J, Andrikovics H, Illes A, Demeter J, Homor L, Udvardy M, Egyed M. Karadi E, et al. Eur J Haematol. 2023 Aug;111(2):263-270. doi: 10.1111/ejh.13992. Epub 2023 May 19. Eur J Haematol. 2023. PMID: 37203365

4

[Neutropenia and sepsis in hematologic patients].

Egyed M, Kollár B, Karádi E, Rajnics P, Kocsondi L, Rumi G. Egyed M, et al. Among authors: karadi e. Orv Hetil. 2006 Oct 22;147(42):2031-3. Orv Hetil. 2006. PMID: 17165603 Hungarian.

5

[Imatinib therapy in chronic myeloid leukemia].

Egyed M, Kollár B, Rajnics P, Karádi E, Matolcsi A. Egyed M, et al. Among authors: karadi e. Orv Hetil. 2008 Aug 10;149(32):1509-12. doi: 10.1556/OH.2008.28354. Orv Hetil. 2008. PMID: 18672441 Hungarian.

6

Increased Lipocalin 2 level may have important role in thrombotic events in patients with polycythemia vera and essential thrombocythemia.

Rajnics P, Kellner Á, Karádi É, Moizs M, Bödör C, Király PA, Marosvári D, Andrikovics H, Egyed M. Rajnics P, et al. Among authors: karadi e. Leuk Res. 2016 Sep;48:101-6. doi: 10.1016/j.leukres.2016.04.016. Epub 2016 Apr 28. Leuk Res. 2016. PMID: 27161323

7

Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.

Dombi P, Illés Á, Demeter J, Homor L, Simon Z, Karadi E, Udvardy M, Egyed M. Dombi P, et al. Among authors: karadi e. Eur J Haematol. 2017 Feb;98(2):106-111. doi: 10.1111/ejh.12806. Epub 2016 Sep 19. Eur J Haematol. 2017. PMID: 27557754

8

[An audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the essential thrombocythaemic patients].

Dombi P, Illés Á, Demeter J, Homor L, Simon Z, Udvardy M, Karádi É, Kellner Á, Egyed M. Dombi P, et al. Among authors: karadi e. Orv Hetil. 2017 Jan;158(3):111-116. doi: 10.1556/650.2017.30638. Orv Hetil. 2017. PMID: 28110571 Hungarian.

9

[Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the Polycythemia vera patients].

Dombi P, Illés Á, Demeter J, Homor L, Simon Z, Kellner Á, Karádi É, Valasinyószki E, Udvardy M, Egyed M. Dombi P, et al. Among authors: karadi e. Orv Hetil. 2017 Jun;158(23):901-909. doi: 10.1556/650.2017.30766. Orv Hetil. 2017. PMID: 28580853 Hungarian.

10

Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin.

Kellner A, Dombi P, Illes A, Demeter J, Homor L, Ercsei I, Simon Z, Karadi E, Herczeg J, Gy Korom V, Gasztonyi Z, Szerafin L, Udvardy M, Egyed M. Kellner A, et al. Among authors: karadi e. Eur J Haematol. 2020 Oct;105(4):408-418. doi: 10.1111/ejh.13459. Epub 2020 Jul 1. Eur J Haematol. 2020. PMID: 32557810

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11 results

Search Page